Counterpoint - The end point: Less is more

Journal of Diabetes Science and Technology

Volumn 5, Issue 5, 2011, Pages 1290-1293

  Fleming, G Alexander ^a  

^a Kinexum LLC   (United States)

Author keywords

Clinical trials; Diabetes treatment; Hemoglobin A1c; Hypoglycemia

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; HUMAN; METABOLISM; NOTE;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84857420652     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500539     Document Type: Note

References (11)

1. Muchmore D. The end point is just the beginning. J Diabetes Sci Technol. 2011;5(5):1287-9.
2. Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther. 2007,29(8):1607-19.
3. Eldor R, Raz I. The individualized target HbA1c: a new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud. 2009;6(1):6-12.
4. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
5. Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA; Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators. Efects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9626):1761-8.
6. The Cardiac Arrhythmia Suppression Trial II Investigators. Efect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327(4):227-33.
7. ACCORD. www.accordtrial.org.
8. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Gof DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med. 2008;358(24):2545-59.
9. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology. 1997;49(1):229-39.
10. Merkies IS, Lauria G. 131st ENMC international workshop: selection of outcome measures for peripheral neuropathy clinical trials 10-12 December 2004, Naarden, The Netherlands. Neuromuscul Disord. 2006;16(2):149-56.
11. Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications. 2010;24(5):354-60.